MCID: MLT006
MIFTS: 48

Multidrug-Resistant Tuberculosis

Categories: Infectious diseases

Aliases & Classifications for Multidrug-Resistant Tuberculosis

MalaCards integrated aliases for Multidrug-Resistant Tuberculosis:

Name: Multidrug-Resistant Tuberculosis 12 15
Tuberculosis, Multidrug-Resistant 44 73
Tuberculosis Multidrug-Resistant 55

Classifications:



External Ids:

Disease Ontology 12 DOID:401
MeSH 44 D018088
NCIt 50 C128415
UMLS 73 C0206526

Summaries for Multidrug-Resistant Tuberculosis

Disease Ontology : 12 A tuberculosis that is resistant to isoniazid and rifampicin, the two most powerful first-line anti-TB drugs.

MalaCards based summary : Multidrug-Resistant Tuberculosis, also known as tuberculosis, multidrug-resistant, is related to mycobacterium tuberculosis 1 and leprosy 3. An important gene associated with Multidrug-Resistant Tuberculosis is INHA (Inhibin Subunit Alpha), and among its related pathways/superpathways are Toxoplasmosis and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Sirturo and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and lung, and related phenotypes are digestive/alimentary and neoplasm

Wikipedia : 76 Multi-drug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria... more...

Related Diseases for Multidrug-Resistant Tuberculosis

Diseases related to Multidrug-Resistant Tuberculosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 122)
# Related Disease Score Top Affiliating Genes
1 mycobacterium tuberculosis 1 30.9 IL10 INHA SLC11A1 TNF VDR
2 leprosy 3 30.3 IL10 SLC11A1 TNF
3 lymphadenitis 30.3 IL10 SLC11A1 TNF
4 pulmonary tuberculosis 30.3 IL10 INHA SLC11A1 TNF VDR
5 human immunodeficiency virus infectious disease 10.4
6 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.3
7 hypothyroidism 10.3
8 punctate inner choroidopathy 10.3 IL10 TNF
9 tropical endomyocardial fibrosis 10.3 IL10 TNF
10 endomyocardial fibrosis 10.3 IL10 TNF
11 microscopic polyangiitis 10.2 IL10 TNF
12 multifocal choroiditis 10.2 IL10 TNF
13 choroiditis 10.2 IL10 TNF
14 tungiasis 10.2 IL10 TNF
15 transient hypogammaglobulinemia 10.2 IL10 TNF
16 cow milk allergy 10.2 IL10 TNF
17 trichuriasis 10.2 IL10 TNF
18 idiopathic achalasia 10.2 IL10 TNF
19 mucocutaneous leishmaniasis 10.2 IL10 TNF
20 clonorchiasis 10.2 IL10 TNF
21 trachoma 10.2 IL10 TNF
22 adult dermatomyositis 10.2 TNF VDR
23 autoimmune gastritis 10.2 IL10 TNF
24 nontuberculous mycobacterial lung disease 10.2 SLC11A1 TNF
25 autoimmune disease of eyes, ear, nose and throat 10.2 IL10 TNF
26 campylobacteriosis 10.2 SLC11A1 VDR
27 intermediate uveitis 10.2 IL10 TNF
28 orofacial granulomatosis 10.2 IL10 TNF
29 transverse myelitis 10.2 IL10 TNF
30 primary systemic mycosis 10.2 IL10 TNF
31 multicentric castleman disease 10.2 ABCB1 IL10
32 soft tissue sarcoma 10.2 ABCB1 TNF
33 mycoplasma pneumoniae pneumonia 10.2 IL10 TNF
34 poliomyelitis 10.2 IL10 TNF
35 buruli ulcer 10.2 IL10 SLC11A1
36 microsporidiosis 10.2 ABCB1 DEFA1
37 diabetes mellitus 10.2
38 eales disease 10.2 IL10 TNF
39 skin conditions 10.2 IL1A TNF
40 plasmablastic lymphoma 10.2 ABCB1 VDR
41 hemorrhagic fever 10.2 IL10 TNF
42 scabies 10.1 IL10 IL1A
43 spotted fever 10.1 IL10 TNF
44 bacterial infectious disease 10.1 IL10 SLC11A1 TNF
45 west nile fever 10.1 DEFA1 DEFA3
46 testicular disease 10.1 IL10 SLC11A1 TNF
47 irritant dermatitis 10.1 IL1A TNF
48 brucellosis 10.1 IL10 SLC11A1 TNF
49 cutaneous leishmaniasis 10.1 IL10 SLC11A1 TNF
50 visceral leishmaniasis 10.1 IL10 SLC11A1 TNF

Graphical network of the top 20 diseases related to Multidrug-Resistant Tuberculosis:



Diseases related to Multidrug-Resistant Tuberculosis

Symptoms & Phenotypes for Multidrug-Resistant Tuberculosis

MGI Mouse Phenotypes related to Multidrug-Resistant Tuberculosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 ABCB1 IL10 INHA SLC11A1 TNF VDR
2 neoplasm MP:0002006 9.02 IL10 IL1A INHA SLC11A1 TNF

Drugs & Therapeutics for Multidrug-Resistant Tuberculosis

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Sirturo 18 BEDAQUILINE FUMARATE Janssen Therapeutics December 2012

Drugs for Multidrug-Resistant Tuberculosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 100986-85-4 149096
2
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Not Applicable 82419-36-1 4583
3
Linezolid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 165800-03-3 441401
4
Clarithromycin Approved Phase 4,Phase 3 81103-11-9 84029
5
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-85-3 3767
6
Kanamycin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 8063-07-8, 59-01-8 6032
7
Moxifloxacin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 354812-41-2, 151096-09-2 152946
8
Capreomycin Approved Phase 4,Not Applicable 11003-38-6 3000502
9
Pyrazinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 98-96-4 1046
10
Amikacin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 37517-28-5 37768
11
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13292-46-1 5458213 5381226
12
Ethionamide Approved Phase 4,Phase 2,Phase 3,Not Applicable 536-33-4 2761171
13
Ethambutol Approved Phase 4,Phase 3,Phase 2,Not Applicable 74-55-5 3279 14052
14
Bedaquiline Approved Phase 4,Phase 2,Phase 3,Phase 1 843663-66-1
15
Clofazimine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2030-63-9 2794
16
Prothionamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 14222-60-7 666418
17
Rifabutin Approved, Investigational Phase 4,Phase 2,Not Applicable 72559-06-9 6323490
18
Cycloserine Approved Phase 4,Phase 2,Phase 3,Not Applicable 68-41-7 6234 401
19
Amoxicillin Approved, Vet_approved Phase 4,Phase 2 26787-78-0 33613
20
Aminosalicylic Acid Approved Phase 4,Phase 2,Phase 3,Not Applicable 65-49-6 4649
21
Streptomycin Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 57-92-1 19649
22
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
23
Cilastatin Approved, Investigational Phase 4 82009-34-5 6435415 5280454
24
Azithromycin Approved Phase 4,Phase 2 83905-01-5 55185 447043
25
Meropenem Approved, Investigational Phase 4 119478-56-7 64778 441130
26
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
27 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
28 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
29 Renal Agents Phase 4,Phase 3,Phase 2,Not Applicable
30 Anti-Infective Agents, Urinary Phase 4,Phase 3,Phase 2,Not Applicable
31 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
35 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Norgestimate, ethinyl estradiol drug combination Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Clavulanic Acids Phase 4,Phase 2
41 Amoxicillin-Potassium Clavulanate Combination Phase 4,Phase 2
42 Thioacetazone Phase 4
43 beta-Lactamase Inhibitors Phase 4
44 Estradiol valerate Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 979-32-8
45
Norgestimate Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 35189-28-7 6540478
46
Polyestradiol phosphate Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 28014-46-2
47
Estradiol Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 50-28-2 5757
48
Ethinyl Estradiol Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 57-63-6 5991
49
Aldesleukin Approved Phase 2, Phase 3 85898-30-2, 110942-02-4
50
Permethrin Approved, Investigational Phase 3 52645-53-1 40326

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis Completed NCT00495339 Phase 4 Levofloxacin
2 Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients Completed NCT01521364 Phase 4 Addition of different doses of clarithromycin.
3 Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya Completed NCT00850915 Phase 4
4 The Individualized M(X) Drug-resistant TB Treatment Strategy Study Recruiting NCT03237182 Phase 4 Individualized TB treatment with multiple drugs;Standardized TB treatment with multiple drugs
5 Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide Unknown status NCT02120638 Phase 3 Pyrazinamide containing regimen;Regimen without Pyrazinamide
6 An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis Unknown status NCT02454205 Phase 2, Phase 3 Linezolid;Bedaquiline;Levofloxacin;Pyrazinamide;Isoniazid;Ethionamide;Terizidone;Moxifloxacin;Kanamycin
7 Safety and Efficacy Trial of Delamanid for 6 Months in Patients With Multidrug Resistant Tuberculosis Completed NCT01424670 Phase 3 Delamanid;Placebo;Optimized Background Regimen (OBR);Antiretrovirals (ARVs)
8 High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis Completed NCT00513396 Phase 2, Phase 3 Isoniazid;Placebo
9 Optimization of the TB Treatment Regimen Cascade Completed NCT02153528 Phase 3 double rimfampicin;Standard TB treatment
10 Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV Completed NCT01061593 Phase 3
11 Shortening Treatment by Advancing Novel Drugs Completed NCT02342886 Phase 3 Moxifloxacin;PA-824;Pyrazinamide;HRZE (Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol combination tablet);HR (rifampicin plus isoniazid combination tablets)
12 Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB Recruiting NCT03069534 Phase 2, Phase 3 RhIL-2
13 The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB Recruiting NCT02409290 Phase 3 Regimen A locally-used WHO-approved MDR-TB regimen;Moxifloxacin;Clofazimine;Ethambutol;Pyrazinamide;Isoniazid;Prothionamide;Kanamycin;Levofloxacin;Bedaquiline
14 Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix) Recruiting NCT03086486 Phase 3 Pretomanid;Linezolid;Bedaquiline;Placebo Linezolid
15 Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) Recruiting NCT02589782 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
16 Evaluating Newly Approved Drugs for Multidrug-resistant TB Recruiting NCT02754765 Phase 3 Bedaquiline;Delamanid;Clofazimine;Levofloxacin;Moxifloxacin;Linezolid;Pyrazinamide
17 FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis Recruiting NCT02607449 Phase 3 FS-1;Placebo
18 A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis Active, not recruiting NCT02333799 Phase 3 Bedaquiline;PA-824;Linezolid
19 TB Immunotherapy Trial With Heat-killed M. Vaccae Enrolling by invitation NCT01977768 Phase 3
20 Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients Not yet recruiting NCT03568383 Phase 3 Delamanid (DLM);Isoniazid (INH)
21 Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients Terminated NCT01055145 Phase 3 levofloxacin, moxifloxacin
22 A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis Withdrawn NCT01600963 Phase 3 Arm A Double-blind Phase: TMC207;Arm B Double-blind Phase: Placebo;Treatment Failure During Double-blind Phase: TMC207;Treatment Failure During Follow-up Phase: TMC207
23 Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin Withdrawn NCT02975570 Phase 3 Delamanid;Linezolid;Levofloxacin;Pyrazinamide;WHO MDR-TB regimen
24 Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis Unknown status NCT01994460 Phase 2 Linezolid;Ethambutol
25 To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB. Completed NCT00910871 Phase 2 TMC207;Background Regimen (BR) for MDR-TB
26 An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) Completed NCT02365623 Phase 2 TMC207 (bedaquiline);Background Regimen (BR)
27 TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB Completed NCT00664313 Phase 1, Phase 2 Linezolid;Placebo
28 TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB). Completed NCT00449644 Phase 2 TMC207;Placebo;Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)
29 A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) Completed NCT00685360 Phase 2 OPC-67683;OPC-67683;Placebo
30 Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB) Completed NCT00691392 Phase 1, Phase 2 Linezolid;Microcrystalline Methylcellulose - Placebo
31 Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis Completed NCT01131351 Phase 2 OPC-67683
32 A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 Completed NCT02573350 Phase 2 Delamanid
33 Metronidazole for Pulmonary Tuberculosis (South Korea) Completed NCT00425113 Phase 2 Metronidazole
34 Linezolid to Treat Extensively-Drug Resistant Tuberculosis Completed NCT00727844 Phase 2 Immediate Start Linezolid;Delayed Start Linezolid
35 Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients Completed NCT01222338 Phase 2
36 A Phase 2 Open Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. Completed NCT02193776 Phase 2 PA-824;bedaquiline;moxifloxacin;pyrazinamide;isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet
37 Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB Recruiting NCT02354014 Phase 2 Bedaquiline (TMC207);Background Regimen (BR)
38 Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB Recruiting NCT03141060 Phase 1, Phase 2 Delamanid;Optimized multidrug background regimen (OBR) for children with MDR-TB
39 Treatment Shortening of MDR-TB Using Existing and New Drugs Recruiting NCT02619994 Phase 2 Linezolid;Delamanid;Levofloxacin;Pyrazinamide;Locally-used WHO-approved MDR-TB regimen in Korea
40 Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis Recruiting NCT02906007 Phase 1, Phase 2 Bedaquiline
41 Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis Recruiting NCT03160638 Phase 2 Azithromycin 250 mg
42 Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly Recruiting NCT02415985 Phase 2 Lopinavir/r will be supplied by NHSO/GPO;Rifabutin
43 A 6-Month Safety, Efficacy, and PK Trial of Delamanid in Pediatric Patients With Multidrug Resistant Tuberculosis Active, not recruiting NCT01859923 Phase 2 100 mg Delamanid;50 mg Delamanid;25 mg Pediatric Formulation Delamanid;10 mg Delamanid Pediatric Formulation;5 mg Delamanid Pediatric Formulation;Optimized Background Regimen
44 Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB Active, not recruiting NCT01918397 Phase 2 Levofloxacin;Optimized background regimen (OBR)
45 Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis Active, not recruiting NCT02583048 Phase 2 Bedaquiline;Delamanid;Dolutegravir
46 Safety of RUTI® Vaccination in MDR-TB Patients Not yet recruiting NCT02711735 Phase 2
47 Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis Completed NCT01856634 Phase 1 100 mg Delamanid;50 mg Delamanid;25 mg Pediatric Formulation Delamanid;10 mg Delamanid Pediatric Formulation;5 mg Delamanid Pediatric Formulation;Optimized Background Regimen
48 Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
49 Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells Recruiting NCT03575299 Phase 1 Conventional treatment
50 Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic Recruiting NCT02503839 Phase 1 etoricoxib

Search NIH Clinical Center for Multidrug-Resistant Tuberculosis

Cochrane evidence based reviews: tuberculosis, multidrug-resistant

Genetic Tests for Multidrug-Resistant Tuberculosis

Anatomical Context for Multidrug-Resistant Tuberculosis

MalaCards organs/tissues related to Multidrug-Resistant Tuberculosis:

41
Testes, T Cells, Lung, Skin, Liver, Bone, Lymph Node

Publications for Multidrug-Resistant Tuberculosis

Articles related to Multidrug-Resistant Tuberculosis:

(show top 50) (show all 1197)
# Title Authors Year
1
Genome sequence of Mycobacterium yongonense RT 955-2015 isolate from a patient misdiagnosed with multidrug-resistant tuberculosis: First clinical detection in Tanzania. ( 29702266 )
2018
2
Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. ( 29297422 )
2018
3
Multidrug-resistant Tuberculosis Lymphadenitis as the Initial Presentation of Secondary Multidrug-resistant Tuberculosis: A Case Report. ( 29805932 )
2018
4
Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China. ( 29437632 )
2018
5
Sequelae of pulmonary multidrug-resistant tuberculosis at the completion of treatment. ( 29319026 )
2018
6
Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia. ( 29944658 )
2018
7
Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. ( 29416359 )
2018
8
Household context and psychosocial impact of childhood multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa. ( 29297424 )
2018
9
Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study. ( 29970076 )
2018
10
Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management. ( 29319042 )
2018
11
Depression among multidrug-resistant tuberculosis patients in Punjab, Pakistan: a large cross-sectional study. ( 29914603 )
2018
12
Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia. ( 29855354 )
2018
13
Diagnostic accuracy and utility of a new molecular assay for multidrug-resistant tuberculosis: FluoroType MTBDR. ( 29976588 )
2018
14
Treatment of Multidrug-Resistant Tuberculosis Infection in Children. ( 29742640 )
2018
15
Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug-Resistant Tuberculosis. ( 29280429 )
2018
16
The use of whole-genome sequencing inA cluster investigation of a multidrug-resistant tuberculosis outbreak. ( 29748309 )
2018
17
Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis. ( 29788331 )
2018
18
Multidrug-Resistant Tuberculosis in the End Tuberculosis EraMultidrug-Resistant Tuberculosis in the End Tuberculosis Era. ( 29924256 )
2018
19
Sequelae of multidrug-resistant tuberculosis: protocol for a systematic review and meta-analysis. ( 29440162 )
2018
20
Have compensatory mutations facilitated the current epidemic of multidrug-resistant tuberculosis? ( 29872078 )
2018
21
Characteristics and outcome of multidrug-resistant tuberculosis in a low-incidence area. ( 29887187 )
2018
22
Hearing loss with Kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh. ( 29348152 )
2018
23
Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis. ( 29791488 )
2018
24
Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study. ( 29297426 )
2018
25
Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. ( 29280409 )
2018
26
Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert<sup>Ar</sup> MTB/RIF for People Living with HIV/AIDS and People with Presumptive Multidrug-resistant Tuberculosis. ( 29862440 )
2018
27
Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up. ( 29394358 )
2018
28
Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis. ( 29791559 )
2018
29
Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome. ( 29942536 )
2018
30
Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. ( 29374587 )
2018
31
Social support a key factor for adherence to multidrug-resistant tuberculosis treatment. ( 29332647 )
2018
32
Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis. ( 29806961 )
2018
33
Intermediate Susceptibility Dose-Dependent Breakpoints For High Dose Rifampicin, Isoniazid and Pyrazinamide Treatment in multidrug-resistant tuberculosis Programmes. ( 29697766 )
2018
34
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling. ( 30249697 )
2018
35
Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients' data analysis for outcome and effectiveness of the current regimens. ( 30261852 )
2018
36
Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study. ( 30287613 )
2018
37
Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot. ( 30319946 )
2018
38
Early Detection and Analysis of Children with Multidrug-Resistant Tuberculosis of the Spine. ( 30326699 )
2018
39
Outbreak of Tuberculosis and Multidrug-Resistant Tuberculosis, Mbuji-Mayi Central Prison, Democratic Republic of the Congo. ( 30334730 )
2018
40
Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. ( 30339803 )
2018
41
Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China. ( 30342251 )
2018
42
Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study. ( 30342828 )
2018
43
Multidrug-Resistant Tuberculosis in Côte d'Ivoire from 1995 to 2016: Results of National Surveys. ( 30345089 )
2018
44
Rapid drug susceptibility testing and treatment outcomes for multidrug-resistant tuberculosis in Peru. ( 30355416 )
2018
45
Compensatory evolution drives multidrug-resistant tuberculosis in Central Asia. ( 30373719 )
2018
46
Causal inference with multiple concurrent medications: A comparison of methods and an application in multidrug-resistant tuberculosis. ( 30381005 )
2018
47
Unexpected Pregnancy during Treatment of Multidrug-resistant Tuberculosis. ( 30407162 )
2018
48
Frequency of Circulating CD4+Ki67+HLA-DR- T Regulatory Cells Prior to Treatment for Multidrug Resistant Tuberculosis Can Differentiate the Severity of Disease and Predict Time to Culture Conversion. ( 30410488 )
2018
49
The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China. ( 30446638 )
2018
50
Delay in diagnosis and treatment among adult multidrug resistant tuberculosis patients in Yangon Regional Tuberculosis Center, Myanmar: a cross-sectional study. ( 30458776 )
2018

Variations for Multidrug-Resistant Tuberculosis

Expression for Multidrug-Resistant Tuberculosis

Search GEO for disease gene expression data for Multidrug-Resistant Tuberculosis.

Pathways for Multidrug-Resistant Tuberculosis

GO Terms for Multidrug-Resistant Tuberculosis

Cellular components related to Multidrug-Resistant Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.1 DEFA1 DEFA3 IL10 IL1A INHA TNF

Biological processes related to Multidrug-Resistant Tuberculosis according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.88 IL10 IL1A INHA TNF
2 positive regulation of gene expression GO:0010628 9.86 IL1A SLC11A1 TNF VDR
3 inflammatory response GO:0006954 9.83 IL10 IL1A SLC11A1 TNF
4 immune response GO:0006955 9.8 DEFA1 IL10 IL1A SLC11A1 TNF
5 defense response GO:0006952 9.74 DEFA1 DEFA3 TNF
6 defense response to Gram-positive bacterium GO:0050830 9.69 DEFA1 DEFA3 TNF
7 defense response to Gram-negative bacterium GO:0050829 9.67 DEFA1 DEFA3 SLC11A1
8 defense response to fungus GO:0050832 9.62 DEFA1 DEFA3
9 negative regulation of interleukin-6 production GO:0032715 9.61 IL10 TNF
10 positive regulation of cytokine production GO:0001819 9.61 SLC11A1 TNF
11 regulation of synapse organization GO:0050807 9.6 IL10 TNF
12 innate immune response in mucosa GO:0002227 9.59 DEFA1 DEFA3
13 intracellular estrogen receptor signaling pathway GO:0030520 9.58 DEFA1 DEFA3
14 cellular response to lipopolysaccharide GO:0071222 9.56 DEFA1 DEFA3 IL10 TNF
15 negative regulation of growth of symbiont in host GO:0044130 9.55 IL10 TNF
16 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.54 IL10 TNF
17 antimicrobial humoral response GO:0019730 9.54 DEFA1 DEFA3 SLC11A1
18 membrane disruption in other organism GO:0051673 9.48 DEFA1 DEFA3
19 endothelial cell apoptotic process GO:0072577 9.46 IL10 TNF
20 negative regulation of cytokine secretion involved in immune response GO:0002740 9.43 IL10 TNF
21 positive regulation of cytokine secretion GO:0050715 9.33 IL10 IL1A TNF
22 receptor biosynthetic process GO:0032800 9.32 IL10 TNF
23 defense response to protozoan GO:0042832 9.13 DEFA1 IL10 SLC11A1
24 defense response to bacterium GO:0042742 9.02 DEFA1 DEFA3 IL10 SLC11A1 TNF
25 positive regulation of transcription by RNA polymerase II GO:0045944 10.02 IL10 IL1A SLC11A1 TNF VDR

Molecular functions related to Multidrug-Resistant Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IL10 IL1A INHA TNF

Sources for Multidrug-Resistant Tuberculosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....